Neuland Laboratories Ltd
NSE:NEULANDLAB
Intrinsic Value
Neuland Laboratories Ltd. manufactures and exports bulk pharmaceutical ingredients and intermediates for the generics industry. [ Read More ]
The intrinsic value of one
NEULANDLAB
stock under the Base Case scenario is
4 936.3783
INR.
Compared to the current market price of 6 109.0498 INR,
Neuland Laboratories Ltd
is
Overvalued by 19%.
Neuland Laboratories Ltd's market capitalization is 78.4B INR.
NEULANDLAB stock price is 6 109.0498 INR.
NEULANDLAB stock (4 936.3783 INR) is 19% less than its price (6109.0498 INR).
NEULANDLAB stock (3 655.4249 INR) is 40% less than its price (6109.0498 INR). Open DCF Valuation
NEULANDLAB stock price (6109.0498 INR) is 2% less than its Relative Value (6 217.3316 INR). Open Relative Valuation
NEULANDLAB has upside potential of 39% compared to the average analyst price target.
Open Wall St Estimates
NEULANDLAB has positive Net Income for the last twelve months.
NEULANDLAB has positive three-year average ROIC (Return on Invested Capital): 12%. The company is efficient at using invested capital to generate operating income.
NEULANDLAB has positive Operating Income for the last twelve months.
NEULANDLAB's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 21%.
NEULANDLAB has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
NEULANDLAB's Revenue has grown by an exceptional 31% over the past 12 months.
NEULANDLAB's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
NEULANDLAB has positive Free Cash Flow for the last twelve months.
NEULANDLAB's ROE (Return on Equity) for the past 12 months is very high and is equal to 26%.
NEULANDLAB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 8% to 21%.
NEULANDLAB's Revenue has been growing by 18% per year for the last 3 years.
NEULANDLAB's ROE (Return on Equity) has significantly increased in the last 3 years from 11% to 26%.
NEULANDLAB's short-term assets (9B INR) exceed its short-term liabilties (4B INR).
NEULANDLAB has positive Gross Profit for the last twelve months.
NEULANDLAB has negative Net Debt. This means that the company has more cash and short-term investments (1B INR) than debt (541m INR).
NEULANDLAB's long-term assets (18B INR) exceed its long-term liabilties (5B INR).
NEULANDLAB's D/E (Debt to Equity) is very low and is equal to 0.04.
NEULANDLAB's Altman Z-Score is very high and is equal to 11.64.
NEULANDLAB earns more than enough operating income (4B INR) to safely cover interest payments on its debt (141m INR).
Valuation Backtest
Neuland Laboratories Ltd
Run backtest to discover the historical profit from buying and selling
NEULANDLAB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Neuland Laboratories Ltd
Balance Sheet Decomposition
Neuland Laboratories Ltd
| Current Assets | 9.2B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 3.7B |
| Other Current Assets | 4.3B |
| Non-Current Assets | 9.1B |
| Long-Term Investments | 287.7m |
| PP&E | 5.7B |
| Intangibles | 2.8B |
| Other Non-Current Assets | 321.8m |
| Current Liabilities | 4.3B |
| Accounts Payable | 1.9B |
| Other Current Liabilities | 2.4B |
| Non-Current Liabilities | 1.2B |
| Long-Term Debt | 541.2m |
| Other Non-Current Liabilities | 680.5m |
Earnings Waterfall
Neuland Laboratories Ltd
|
Revenue
|
15.6B
INR
|
|
Cost of Revenue
|
-7.3B
INR
|
|
Gross Profit
|
8.2B
INR
|
|
Operating Expenses
|
-4.2B
INR
|
|
Operating Income
|
4B
INR
|
|
Other Expenses
|
-1B
INR
|
|
Net Income
|
3B
INR
|
Free Cash Flow Analysis
Neuland Laboratories Ltd
| INR | |
| Free Cash Flow | INR |
NEULANDLAB Profitability Score
Profitability Due Diligence
Neuland Laboratories Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Neuland Laboratories Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
NEULANDLAB Solvency Score
Solvency Due Diligence
Neuland Laboratories Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
Neuland Laboratories Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEULANDLAB Price Targets Summary
Neuland Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for
NEULANDLAB
is 8 466 INR
with a low forecast of 7 575 INR and a high forecast of 9 555 INR.
Shareholder Return
NEULANDLAB Price
Neuland Laboratories Ltd
| Average Annual Return | 45.07% |
| Standard Deviation of Annual Returns | 83.58% |
| Max Drawdown | -59% |
| Market Capitalization | 78.4B INR |
| Shares Outstanding | 12 829 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Neuland Laboratories Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Neuland Laboratories Ltd. manufactures and exports bulk pharmaceutical ingredients and intermediates for the generics industry. The company is headquartered in Hyderabad, Telangana and currently employs 1,521 full-time employees. The firm is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The firm operates through manufacture of active pharmaceutical ingredients and allied services. The firm has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services. The Company’s capabilities include FBRM, research and development, peptide laboratory, poly block reactors, laboratory reactors, heating and cooling systems, hazardous and wet laboratory, PID Laboratory Unit-III, PID Laboratory B-S Unit-I, and other lab equipment. The firm has 3 manufacturing facilities and one R&D facility in Hyderabad.
Contact
IPO
Employees
Officers
The intrinsic value of one
NEULANDLAB
stock under the Base Case scenario is
4 936.3783
INR.
Compared to the current market price of 6 109.0498 INR,
Neuland Laboratories Ltd
is
Overvalued by 19%.
You don't have any saved screeners yet
